Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director · President and CEO | July 28, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 68,793 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 84,000 · Balance 152,793 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 84,000 · Balance 68,793 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 84,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $32.45 | $0.00 |
DisclosureSEC source: 0001140361-22-006900 · form4.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 22:13 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-21-005088 · doc1.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2030-02-25 F2 · derivative.exercise_date: On February 25, 2020, the reporting person was granted an option to purchase 50,000 ordinary shares. The shares subject to the option vested in full based on the achievement of certain performance criteria. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 22:13 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001567619-21-005088 · doc1.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,601 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 12 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,601 Underlying: Ordinary Shares · 140,601 shares Expires 2028-02-21 F9 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 187,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 140,601 ordinary shares, having an exercise price of $22.85 per ordinary share. F10 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 47/48 of the total number of shares subject to the option on the one year anniversary of the date of grant and with respect to 1/48 of the total number of shares subject to the option on February 21, 2022, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 187,000 | Not disclosed Strike: $33.10 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 11 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 187,000 shares Expires 2028-02-21 F9 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 187,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 140,601 ordinary shares, having an exercise price of $22.85 per ordinary share. F8 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 10 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Ordinary Shares · 62,500 shares Expires 2027-02-22 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 120,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 62,500 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 120,000 | Not disclosed Strike: $55.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 9 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,000 shares Expires 2027-02-22 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 120,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 62,500 ordinary shares, having an exercise price of $22.85 per ordinary share. F6 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued employment with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 16,759 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 8 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,759 Underlying: Ordinary Shares · 16,759 shares Expires 2026-11-02 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's ordinary shares granted to the reporting person on November 2, 2016. In exchange, the reporting person received a replacement option, for 16,759 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $45.13 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 7 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,000 shares Expires 2026-11-02 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's ordinary shares granted to the reporting person on November 2, 2016. In exchange, the reporting person received a replacement option, for 16,759 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,125 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 6 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,125 Underlying: Ordinary Shares · 25,125 shares Expires 2026-09-01 F4 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 of the issuer's ordinary shares granted to the reporting person on September 1, 2016. In exchange, the reporting person received a replacement option, for 25,125 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $52.21 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 5 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2026-09-01 F4 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 of the issuer's ordinary shares granted to the reporting person on September 1, 2016. In exchange, the reporting person received a replacement option, for 25,125 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,625 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 4 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Ordinary Shares · 40,625 shares Expires 2026-02-24 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 65,000 of the issuer's ordinary shares granted to the reporting person on February 24, 2016. In exchange, the reporting person received a replacement option, for 40,625 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $34.61 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2026-02-24 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 65,000 of the issuer's ordinary shares granted to the reporting person on February 24, 2016. In exchange, the reporting person received a replacement option, for 40,625 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 59,090 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,090 Underlying: Ordinary Shares · 59,090 shares Expires 2025-03-11 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 65,000 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 59,090 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:41 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $27.81 | Not disclosed |
DisclosureSEC source: 0001567619-21-004310 · doc1.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2025-03-11 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 65,000 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 59,090 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-20-015757 · doc1.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,074 Underlying: Ordinary Shares · 10,000 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.41 | $64,100.00 |
DisclosureSEC source: 0001567619-20-015757 · doc1.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:13 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-20-005017 · doc1.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 245,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005428 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Ordinary Shares · 245,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 620,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017928 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,000 Underlying: Ordinary Shares · 620,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:08 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 187,000 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0000899243-18-005304 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,000 Underlying: Ordinary Shares · 187,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-17-022967 · doc4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,074 Underlying: Ordinary Shares · 2,800 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,800 | $70.00 | $196,000.00 |
DisclosureSEC source: 0000899243-17-022967 · doc4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,800 | $6.41 | $17,948.00 |
DisclosureSEC source: 0000899243-17-022967 · doc4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 25,163 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-17-006338 · doc4.xml · derivative · entry 4 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,874 Underlying: Ordinary Shares · 25,163 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 12,822 | $61.24 | $785,275.70 |
DisclosureSEC source: 0000899243-17-006338 · doc4.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $61.00 to $61.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 12,341 | $60.28 | $743,972.25 |
DisclosureSEC source: 0000899243-17-006338 · doc4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,615 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $60.00 to $60.995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 25,163 | $6.41 | $161,294.83 |
DisclosureSEC source: 0000899243-17-006338 · doc4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 3,796 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-17-006027 · doc4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,037 Underlying: Ordinary Shares · 3,796 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,796 | $60.00 | $227,760.00 |
DisclosureSEC source: 0000899243-17-006027 · doc4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 3,796 | $6.41 | $24,332.36 |
DisclosureSEC source: 0000899243-17-006027 · doc4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $55.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005221 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Ordinary Shares · 120,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 8,548 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-16-033196 · doc4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,833 Underlying: Ordinary Shares · 8,548 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 8,548 | $55.32 | $472,905.28 |
DisclosureSEC source: 0000899243-16-033196 · doc4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $55.00 to $55.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 8,548 | $6.41 | $54,792.68 |
DisclosureSEC source: 0000899243-16-033196 · doc4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $45.13 | $0.00 |
DisclosureSEC source: 0000899243-16-032768 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2026-11-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on September 30, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 21, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · derivative · entry 6 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,381 Underlying: Ordinary Shares · 5,834 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 21, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,834 | $55.15 | $321,745.10 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · nonDerivative · entry 4 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $55 to $55.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 21, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,834 | $6.41 | $37,395.94 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 14,785 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · derivative · entry 5 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,215 Underlying: Ordinary Shares · 14,785 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 20, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 14,785 | $55.08 | $814,357.80 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,793 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $55 to $55.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2016 Filed Oct 21, 2016 21:23 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 14,785 | $6.41 | $94,771.85 |
DisclosureSEC source: 0000899243-16-032172 · doc4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $52.21 | $0.00 |
DisclosureSEC source: 0000899243-16-028539 · doc4.xml · derivative · entry 2 Kinney Gene G. · CIK 0001564380 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2026-09-01 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on September 1, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.